MX2022005063A - Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. - Google Patents
Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina.Info
- Publication number
- MX2022005063A MX2022005063A MX2022005063A MX2022005063A MX2022005063A MX 2022005063 A MX2022005063 A MX 2022005063A MX 2022005063 A MX2022005063 A MX 2022005063A MX 2022005063 A MX2022005063 A MX 2022005063A MX 2022005063 A MX2022005063 A MX 2022005063A
- Authority
- MX
- Mexico
- Prior art keywords
- edonentan
- agent
- treatment
- receptor antagonists
- endothelin receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928092P | 2019-10-30 | 2019-10-30 | |
| US202063068215P | 2020-08-20 | 2020-08-20 | |
| PCT/US2020/058411 WO2021087399A1 (en) | 2019-10-30 | 2020-10-30 | Treatment of ocular diseases using endothelin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005063A true MX2022005063A (es) | 2022-08-04 |
Family
ID=75715356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005063A MX2022005063A (es) | 2019-10-30 | 2020-10-30 | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US11738007B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4094759A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7664239B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN118203574A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020373065A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3158767A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL292350A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022005063A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087399A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| BR112023022705A2 (pt) * | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| WO2022251710A2 (en) | 2021-05-28 | 2022-12-01 | Sight Sciences, Inc. | Intraocular devices, systems, and methods |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) * | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| JPH0959173A (ja) * | 1995-08-21 | 1997-03-04 | Santen Pharmaceut Co Ltd | 毛様体筋緊張緩和剤 |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| CZ20032350A3 (en) * | 2001-02-02 | 2004-03-17 | Merck Patent Gmbh | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| AR080888A1 (es) | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| ES2813383T3 (es) * | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| JP2018522942A (ja) * | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| WO2017217967A1 (en) * | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| US11286274B2 (en) * | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US10905770B2 (en) * | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| WO2019210194A1 (en) * | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) * | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| BR112023022705A2 (pt) | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
-
2020
- 2020-10-30 JP JP2022525291A patent/JP7664239B2/ja active Active
- 2020-10-30 WO PCT/US2020/058411 patent/WO2021087399A1/en not_active Ceased
- 2020-10-30 IL IL292350A patent/IL292350A/en unknown
- 2020-10-30 MX MX2022005063A patent/MX2022005063A/es unknown
- 2020-10-30 CN CN202410236817.2A patent/CN118203574A/zh active Pending
- 2020-10-30 CN CN202080076957.8A patent/CN114786480B/zh active Active
- 2020-10-30 AU AU2020373065A patent/AU2020373065A1/en active Pending
- 2020-10-30 EP EP22176530.8A patent/EP4094759A1/en active Pending
- 2020-10-30 CA CA3158767A patent/CA3158767A1/en active Pending
- 2020-10-30 EP EP20881057.2A patent/EP4050997A4/en active Pending
-
2022
- 2022-04-29 US US17/733,216 patent/US11738007B2/en active Active
- 2022-04-29 US US17/733,210 patent/US20220257505A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/345,514 patent/US20240189288A1/en active Pending
-
2024
- 2024-12-10 US US18/976,033 patent/US20250099435A1/en active Pending
-
2025
- 2025-04-07 JP JP2025063020A patent/JP2025106418A/ja active Pending
- 2025-11-21 US US19/397,828 patent/US20260076948A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3158767A1 (en) | 2021-05-06 |
| CN114786480A (zh) | 2022-07-22 |
| IL292350A (en) | 2022-06-01 |
| JP2022554277A (ja) | 2022-12-28 |
| AU2020373065A1 (en) | 2022-05-26 |
| CN114786480B (zh) | 2024-03-29 |
| WO2021087399A1 (en) | 2021-05-06 |
| JP7664239B2 (ja) | 2025-04-17 |
| EP4094759A1 (en) | 2022-11-30 |
| US20260076948A1 (en) | 2026-03-19 |
| US20220257505A1 (en) | 2022-08-18 |
| US11738007B2 (en) | 2023-08-29 |
| CN118203574A (zh) | 2024-06-18 |
| US20220257568A1 (en) | 2022-08-18 |
| US20240189288A1 (en) | 2024-06-13 |
| JP2025106418A (ja) | 2025-07-15 |
| EP4050997A1 (en) | 2022-09-07 |
| EP4050997A4 (en) | 2022-11-30 |
| US20250099435A1 (en) | 2025-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith et al. | Negative lens–induced myopia in infant monkeys: effects of high ambient lighting | |
| Del Amo et al. | Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data | |
| MX2020005240A (es) | Sistemas y metodos para cirugia laser ocular y tratamientos terapeuticos. | |
| GB2540638A8 (en) | Compositions, Formulations and methods for treating ocular diseases | |
| WO2015130821A3 (en) | Illuminated treatment probe for delivering laser energy | |
| Ogawa et al. | Aetiology-specific comparison of long-term outcome of deep anterior lamellar keratoplasty for corneal diseases | |
| Wagner et al. | Sex-and gender-based differences in healthy and diseased eyes | |
| PH12020550409A1 (en) | Anti-trkb monoclonal antibodies and methods of use | |
| EP2279247A4 (en) | STEM CELLS OF THE RETINAL PIGMENTARY EPITHELIUM | |
| BR112022015579A2 (pt) | Composições para tratamento de doenças oculares | |
| Singh et al. | Science and art of cell-based ocular surface regeneration | |
| UY28660A1 (es) | Antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento del glaucoma | |
| MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
| JOP20220115A1 (ar) | معززات خاصة بالخلايا ثنائية القطب-on لتوصيل الجينات الخاصة بالعين | |
| CL2020000479A1 (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfa. | |
| Yagci et al. | Cross-linking treatment and corneal transplant in refractory acremonium keratitis: case report | |
| CO2022013055A2 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| EP4523693A3 (en) | Injectable hydrogels for cell delivery to the vitreous | |
| MX2023006724A (es) | Gotas oftálmicas para tratar el adelgazamiento escleral y método de detección para el agente terapéutico de adelgazamiento escleral. | |
| MX2023012826A (es) | Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina. | |
| MX2022006523A (es) | Composicion que comprende budesonida para uso oftalmico. | |
| MX2019008910A (es) | Acoplamiento en una sola fase de un laser de femtosegundo. | |
| Ghaffariyeh et al. | Amantadine-associated corneal edema | |
| WO2020104578A3 (en) | Modulators of free fatty acid receptor 1 and their use for treatment of diseases | |
| CN203777098U (zh) | 小鼠青光眼研究眼压供给装置 |